Lixte Biotechnology Files 8-K
Ticker: LIXT · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1335105
Sentiment: neutral
Topics: financial-statements, exhibits
Related Tickers: LIXT
TL;DR
LIXT filed an 8-K with updated financials/exhibits, check for details.
AI Summary
Lixte Biotechnology Holdings, Inc. filed an 8-K on September 4, 2024, reporting an event related to its financial statements and exhibits. The filing does not contain specific details about the nature of these financial statements or exhibits, nor does it mention any significant transactions or events.
Why It Matters
This filing indicates that Lixte Biotechnology Holdings, Inc. has submitted updated financial statements or exhibits to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant positive or negative events.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer
- September 4, 2024 (date) — Date of earliest event reported
FAQ
What specific financial statements or exhibits were filed?
The filing does not specify the exact nature or content of the financial statements and exhibits filed, only that they were reported under Item 7 and Item 9.
What is the significance of this 8-K filing for Lixte Biotechnology Holdings, Inc.?
This 8-K filing indicates that the company has submitted required financial information or exhibits to the SEC, which is a standard regulatory requirement.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 4, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
What is the company's telephone number?
The registrant's telephone number, including area code, is (631) 830-7092.
Filing Stats: 394 words · 2 min read · ~1 pages · Grade level 12.4 · Accepted 2024-09-05 16:05:35
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-035144.txt ( ) — 272KB
- lixt-20240904.xsd (EX-101.SCH) — 3KB
- lixt-20240904_def.xml (EX-101.DEF) — 26KB
- lixt-20240904_lab.xml (EX-101.LAB) — 36KB
- lixt-20240904_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 5, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer INDEX TO EXHIBITS Exhibit No. Description 99.1 Press release announcing receipt of U.S. Patent Issue Notification for immune oncology covering combining LIXTE's LB-100 with various innovative cancer immunotherapies 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)